# A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

> **NCT03352453** · PHASE2 · TERMINATED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 138 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Rapastinel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03352453
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-15
- **Primary completion:** 2019-06-21
- **Final completion:** 2019-06-21
- **Target enrollment:** 138 (ACTUAL)
- **Why stopped:** Study stopped due to business reasons.
- **Last updated:** 2020-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03352453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03352453, "A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03352453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*